Current and historical daily PE Ratio for MEI Pharma Inc (
) from 2003 to Jun 04 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. MEI Pharma stock (MEIP) PE ratio as of Jun 04 2024 is 0.73.
More Details
MEI Pharma Inc (MEIP) PE Ratio (TTM) Chart
MEI Pharma Inc (MEIP) PE Ratio (TTM) Historical Data
View and export this data going back to 2003. Start your Free Trial
Total 1242
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| MEI Pharma PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-06-04 | 0.7 | 2024-04-01 | 1.0 |
| 2024-06-03 | 0.7 | 2024-03-28 | 1.0 |
| 2024-05-31 | 0.7 | 2024-03-27 | 1.3 |
| 2024-05-30 | 0.7 | 2024-03-26 | 1.3 |
| 2024-05-29 | 0.7 | 2024-03-25 | 1.3 |
| 2024-05-28 | 0.8 | 2024-03-22 | 1.3 |
| 2024-05-24 | 0.8 | 2024-03-21 | 1.2 |
| 2024-05-23 | 0.8 | 2024-03-20 | 1.2 |
| 2024-05-22 | 0.8 | 2024-03-19 | 1.3 |
| 2024-05-21 | 0.8 | 2024-03-18 | 1.3 |
| 2024-05-20 | 0.8 | 2024-03-15 | 1.3 |
| 2024-05-17 | 0.8 | 2024-03-14 | 1.3 |
| 2024-05-16 | 0.8 | 2024-03-13 | 1.4 |
| 2024-05-15 | 0.8 | 2024-03-12 | 1.4 |
| 2024-05-14 | 0.8 | 2024-03-11 | 1.4 |
| 2024-05-13 | 0.8 | 2024-03-08 | 1.3 |
| 2024-05-10 | 0.8 | 2024-03-07 | 1.2 |
| 2024-05-09 | 0.8 | 2024-03-06 | 1.2 |
| 2024-05-08 | 0.8 | 2024-03-05 | 1.3 |
| 2024-05-07 | 0.8 | 2024-03-04 | 1.4 |
| 2024-05-06 | 0.8 | 2024-03-01 | 1.4 |
| 2024-05-03 | 0.8 | 2024-02-29 | 1.4 |
| 2024-05-02 | 0.8 | 2024-02-28 | 1.4 |
| 2024-05-01 | 0.8 | 2024-02-27 | 1.4 |
| 2024-04-30 | 0.8 | 2024-02-26 | 1.4 |
| 2024-04-29 | 0.8 | 2024-02-23 | 1.4 |
| 2024-04-26 | 0.8 | 2024-02-22 | 1.4 |
| 2024-04-25 | 0.8 | 2024-02-21 | 1.5 |
| 2024-04-24 | 0.8 | 2024-02-20 | 1.5 |
| 2024-04-23 | 0.8 | 2024-02-16 | 1.5 |
| 2024-04-22 | 0.9 | 2024-02-15 | 1.5 |
| 2024-04-19 | 0.8 | 2024-02-14 | 1.6 |
| 2024-04-18 | 0.8 | 2024-02-13 | 1.6 |
| 2024-04-17 | 0.8 | 2024-02-12 | 1.6 |
| 2024-04-16 | 0.8 | 2024-02-09 | 1.6 |
| 2024-04-15 | 0.8 | 2024-02-08 | 1.6 |
| 2024-04-12 | 0.8 | 2024-02-07 | 1.5 |
| 2024-04-11 | 0.9 | 2024-02-06 | 1.6 |
| 2024-04-10 | 1.0 | 2024-02-05 | 1.5 |
| 2024-04-09 | 1.0 | 2024-02-02 | 1.5 |
| 2024-04-08 | 1.0 | 2024-02-01 | 1.5 |
| 2024-04-05 | 1.0 | 2024-01-31 | 1.5 |
| 2024-04-04 | 1.0 | 2024-01-30 | 1.6 |
| 2024-04-03 | 1.0 | 2024-01-29 | 1.5 |
| 2024-04-02 | 1.0 | 2024-01-26 | 1.5 |
MEI Pharma Inc (MEIP) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
MEI Pharma Inc
NAICS : 325412
SIC : 2834
ISIN : US55279B2025
Description
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers